ASH

The American Society of Hematology conference kicked off Saturday and has driven several directional moves in the stock market. The annual event is a four-day meeting attended by hematologists from around the world where advances in the field of hematology and clinical programs are discussed...

The American Society of Hematology's 61st annual meeting is underway in Orlando, Florida. The four-day meeting kicked off Saturday and features a slew of presenters ranging from top pharma companies to tiny biotechs. The ASH, founded in 1958, is a professional organization...

Bluebird bio Inc (NASDAQ: BLUE)'s stock has soared more than 200 percent since the start of 2017, with notable strength coming after the company released impressive data results at the American Society of Hematology conference. The Analyst Maxim Group's Jason McCarthy downgraded bluebird...

Spark Therapeutics Inc (NASDAQ: ONCE) released phase 1/2 SPK-8011 data in hemophilia A treatment over the weekend that fell short of what investors had hoped for. The Analyst UBS' Carter Gould downgraded Spark's stock rating from Buy to Neutral with a price target slashed from $92 to...

The American Society of Hematology's 59th annual meeting continues through Tuesday in Atlanta. Although stocks reacted to the presentation of abstracts in early November, the full presentation elicited incremental reaction, with the direction and magnitude of the moves dependent on the market...

Syros Pharmaceuticals Inc (NASDAQ: SYRS) reported initial clinical data over the weekend from an ongoing Phase 2 study of its SY-1425 and SY-1365 therapies for the treatment of genetically defined acute myeloid leukemia, or AML, and myelodysplastic syndrome, or MDS.  The Analyst...

Spark Therapeutics Inc (NASDAQ: ONCE) reported during the ASH conference an update concerning its SPK-8011 therapy, which has many investors concerned. The Analyst Cantor Fitzgerald's Elemer Piros maintains an Overweight rating on Spark Therapeutics's stock with an unchanged $105 price...

Bluebird bio Inc (NASDAQ: BLUE)'s multiple myeloma therapy coud have a "disruptive impact" on treatment of the disease, according to Goldman Sachs. The Analyst Goldman Sachs' Salveen Richter maintains a Buy rating on bluebird's stock and raised the price target from $186 to...

Bluebird bio Inc (NASDAQ: BLUE)'s encouraging data release over the weekend has many experts and Wall Street analysts excited about the company's prospects in treating sickle cell disease. The Analyst Jefferies' Biren Amin upgraded bluebird's stock rating from Hold to Buy with a...

Global Blood Therapeutics Inc (NASDAQ: GBT), a clinical-stage biopharmaceutical company that focuses on treating blood-based disorders, released results from multiple data presentations during the 59th American Society of Hematology Annual Meeting & Exposition. The Analyst Morgan Stanley'...

On Friday, the Vetr crowd upgraded their rating for Alnylam Pharmaceuticals, Inc.(NASDAQ: ALNY) from its previous position at 1 star (Strong Sell) issued 88 days ago, to 4.5 star (Strong Buy). Crowd sentiment for the stock is edging positive with 66 percent of Vetr user ratings bullish. The...

The American Society of Hematology (ASH) held its annual December meeting in San Diego, where some of the biggest biotech companies announced clinical trial results, new drug updates and future initiatives. In separate reports, Cantor Fitzgerald analysts mentioned their takes on the announcements...

The American Society of Hematology, a 58-year-old organization of hematologists, wraps up its annual meeting in San Diego Tuesday. The conference is key for investors; it features many of the biggest names in the pharmaceutical and biotech industries and serves as a platform to announce new drugs,...

The 90 mg GBT440 data presented by Global Blood Therapeutics Inc (NASDAQ: GBT) at the American Society of Hematology meeting showed “consistent and durable responses”. Wedbush’s Heather Behanna reiterated an Outperform rating on the company, with a price target of $73. What The...

Gbola Amusa of Chardan Capital said although the AAV-based gene therapy (GT) of Uniqure NV (NASDAQ: QURE has better timing, Spark Therapeutics Inc (NASDAQ: ONCE)has better efficacy in hemophilia B patients. Amusa gave the above comments after both companies presented their data at The American...